Last $5.68 USD
Change Today +0.175 / 3.18%
Volume 1.8M
MNKD On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

mannkind corp (MNKD) Snapshot

Open
$5.52
Previous Close
$5.50
Day High
$5.71
Day Low
$5.50
52 Week High
06/30/14 - $11.48
52 Week Low
03/31/14 - $3.80
Market Cap
2.3B
Average Volume 10 Days
4.2M
EPS TTM
$-0.58
Shares Outstanding
405.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MANNKIND CORP (MNKD)

mannkind corp (MNKD) Details

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate is AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company is also developing MedTone and Dreamboat inhaler devices. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

265 Employees
Last Reported Date: 03/3/14
Founded in 1991

mannkind corp (MNKD) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $824.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $718.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $440.8K
Chief Technical Officer and Corporate Vice Pr...
Total Annual Compensation: $459.1K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $387.4K
Compensation as of Fiscal Year 2013.

mannkind corp (MNKD) Key Developments

MannKind Corp. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 03:00 PM

MannKind Corp. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 03:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

Mannkind Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

MannKind Corporation announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the third quarter, the company reported loss from operations was $38,266,000 compared with $44,762,000 a year ago. Loss before benefit for income tax was $36,520,000 compared with $50,818,000 a year ago. Net loss applicable to common stockholders was $36,520,000 compared with $50,818,000 a year ago. Diluted net loss per share to common stockholders was $0.09 compared with $0.17 a year ago. For the nine months, the company reported loss from operations was $149,524,000 compared with $122,784,000 a year ago. Loss before benefit for income tax was $161,941,000 compared with $137,907,000 a year ago. Net loss applicable to common stockholders was $161,941,000 compared with $137,907,000 a year ago. Diluted net loss per share to common stockholders was $0.42 compared with $0.48 a year ago.

MannKind Corp. to Report Q3, 2014 Results on Nov 03, 2014

MannKind Corp. announced that they will report Q3, 2014 results at 5:00 PM, US Eastern Standard Time on Nov 03, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNKD:US $5.68 USD +0.175

MNKD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MNKD.
View Industry Companies
 

Industry Analysis

MNKD

Industry Average

Valuation MNKD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MANNKIND CORP, please visit www.mannkindcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.